Vimarsana
Biggest News Aggregation in the World

Page 4 - Vida Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vida Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vida Ventures Today - Breaking & Trending Today

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction - Ikena Oncology (NASDAQ:IKNA) - Vimarsana News

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction - Ikena Oncology (NASDAQ:IKNA)

Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction - Vimarsana News

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO,...

Five months ago Crunchbase vowed to try and avoid layoffs. Since then A.I. has changed everything - Vimarsana News

Five months ago Crunchbase vowed to try and avoid layoffs. Since then A.I. has changed everything

“It's an existential threat to your business if you don't think of things as in an A.I.-first world,” says Crunchbase CEO Jager McConnell.

Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors - Vimarsana News

Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors

/PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune...

Gilead-backed cell therapy startup Kyverna adds fresh funds for new strategy - Vimarsana News

Gilead-backed cell therapy startup Kyverna adds fresh funds for new strategy

BioPharma